HK1243948A1 - 溴結構域抑制劑 - Google Patents

溴結構域抑制劑

Info

Publication number
HK1243948A1
HK1243948A1 HK18103550.6A HK18103550A HK1243948A1 HK 1243948 A1 HK1243948 A1 HK 1243948A1 HK 18103550 A HK18103550 A HK 18103550A HK 1243948 A1 HK1243948 A1 HK 1243948A1
Authority
HK
Hong Kong
Prior art keywords
bromodomain inhibitor
bromodomain
inhibitor
Prior art date
Application number
HK18103550.6A
Other languages
English (en)
Inventor
Juan Manuel Betancort
Jeffrey Alan Stafford
Ryan Stansfield
James Marvin Veal
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Publication of HK1243948A1 publication Critical patent/HK1243948A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
HK18103550.6A 2015-04-22 2018-03-14 溴結構域抑制劑 HK1243948A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562151205P 2015-04-22 2015-04-22
PCT/US2016/029029 WO2016172618A1 (en) 2015-04-22 2016-04-22 Bromodomain inhibitor

Publications (1)

Publication Number Publication Date
HK1243948A1 true HK1243948A1 (zh) 2018-07-27

Family

ID=57143581

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103550.6A HK1243948A1 (zh) 2015-04-22 2018-03-14 溴結構域抑制劑

Country Status (23)

Country Link
US (1) US20160310423A1 (zh)
EP (1) EP3285770A4 (zh)
JP (1) JP2018513863A (zh)
KR (1) KR20170139119A (zh)
CN (1) CN107613981A (zh)
AR (1) AR104340A1 (zh)
AU (1) AU2016252992A1 (zh)
BR (1) BR112017022691A2 (zh)
CA (1) CA2983446C (zh)
CL (1) CL2017002679A1 (zh)
CO (1) CO2017011482A2 (zh)
EA (1) EA201792317A1 (zh)
EC (1) ECSP17071545A (zh)
HK (1) HK1243948A1 (zh)
IL (1) IL255120B (zh)
MX (2) MX2017013501A (zh)
NZ (1) NZ736630A (zh)
PE (1) PE20180036A1 (zh)
PH (1) PH12017501933A1 (zh)
SG (1) SG11201708627TA (zh)
TW (1) TW201642860A (zh)
WO (1) WO2016172618A1 (zh)
ZA (1) ZA201707186B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
US10702517B2 (en) 2015-04-22 2020-07-07 Celgene Quanticel Research, Inc. Bromodomain inhibitor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN110099685A (zh) * 2016-10-20 2019-08-06 赛尔基因光迪斯研究公司 溴结构域抑制剂
CA3041049A1 (en) 2016-10-27 2018-05-03 Celgene Quanticel Research, Inc. Bromodomain and extra-terminal protein inhibitor combination therapy
AU2019309693B2 (en) * 2018-07-23 2023-03-16 Celgene Quanticel Research, Inc. Process for the preparation of bromodomain inhibitor
EP4294397A1 (en) * 2021-02-22 2023-12-27 Celgene Quanticel Research, Inc. Bromodomain (bet) inhibitor for use in treating prostate cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
PL3640241T3 (pl) * 2013-10-18 2022-12-05 Celgene Quanticel Research, Inc. Inhibitory bromodomeny
CN110099685A (zh) * 2016-10-20 2019-08-06 赛尔基因光迪斯研究公司 溴结构域抑制剂

Also Published As

Publication number Publication date
ZA201707186B (en) 2019-01-30
TW201642860A (zh) 2016-12-16
NZ736630A (en) 2024-03-22
SG11201708627TA (en) 2017-11-29
KR20170139119A (ko) 2017-12-18
EP3285770A1 (en) 2018-02-28
IL255120B (en) 2021-03-25
IL255120A0 (en) 2017-12-31
JP2018513863A (ja) 2018-05-31
WO2016172618A1 (en) 2016-10-27
CL2017002679A1 (es) 2018-05-25
ECSP17071545A (es) 2017-12-01
PE20180036A1 (es) 2018-01-09
EP3285770A4 (en) 2018-10-31
MX2020010899A (es) 2022-02-15
CN107613981A (zh) 2018-01-19
AU2016252992A1 (en) 2017-11-09
PH12017501933A1 (en) 2018-03-19
CA2983446C (en) 2024-04-09
US20160310423A1 (en) 2016-10-27
MX2017013501A (es) 2018-02-09
CO2017011482A2 (es) 2018-01-31
AR104340A1 (es) 2017-07-12
EA201792317A1 (ru) 2018-03-30
CA2983446A1 (en) 2016-10-27
BR112017022691A2 (pt) 2018-07-17

Similar Documents

Publication Publication Date Title
HK1243326A1 (zh) 溴結構域抑制劑
ME03759B (me) Inhibitori bromodomena
DK3256579T3 (en) Cysteinprotease
HK1243415A1 (zh) 溴結構域抑制劑
DK3250592T3 (en) Anti-transthyretin-antistoffer
HK1243948A1 (zh) 溴結構域抑制劑
IL265139B (en) Dopamine-b-hydroxylase inhibitors
GB201513481D0 (en) Inhibitor compounds
GB201505658D0 (en) Inhibitor compounds
GB201517368D0 (en) Value
GB201612860D0 (en) Inhibitors
GB201501004D0 (en) Inhibitors
AU361999S (en) Ballustrade
DK3133099T3 (en) Polymermodificeret polyoldispersion
GB201511951D0 (en) An eyeguard
GB201520949D0 (en) Inhibitors
ZA201807614B (en) Bromodomain inhibitors
IL258458B (en) Peroxyhemiacetal profragrant and proflavor compounds
AU5516P (en) LEP08 Lepidosperma squamatum
AU5511P (en) PTK647 Epichloe coenophiala
GB201522453D0 (en) Inhibitor compounds
AU366552S (en) Nutblock
AU367131S (en) USB-charger
GB201516350D0 (en) Anywhere bankstick
GB201516257D0 (en) Setouting application